
Opinion|Videos|September 25, 2024
Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do you determine the optimal timing and frequency of imaging studies using specific agents to monitor oligometastatic disease progression in prostate cancer patients?
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Emerging Cable-Free, AI-Powered C-Arm System
2
What’s on the Horizon for Breast Imaging Legislation in 2026?
3
FDA Clears New PET/MRI System from Siemens Healthineers
4
Large Mammography Study Suggests Adjunctive AI May Have an Impact in Reducing Interval Breast Cancer Rates
5











